文献速递肿瘤 PET/CT

评估18F-FDG PET/CT在原发灶不明癌症中的效用

Evaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary.
PubMed 文献 · J Nucl Med · 2024-10-01

该研究回顾了Peter MacCallum癌症中心2014至2020年147例颈外原发灶不明癌症(CUP)患者,评估18F-FDG PET/CT检测原发灶的效能及对治疗的影响。PET/CT原发灶检出率为41%,22%患者治疗方案发生改变,37%发现既往隐匿病灶。检出原发灶者中位总生存期19.8个月,未检出者8.5个月(P=0.016)。

要点

  • 18F-FDG PET/CT在颈外CUP中原发灶检出率为41%,22%患者治疗发生改变。
  • 检出原发灶者中位总生存期19.8个月,未检出者8.5个月(P=0.016)。
  • 多变量分析中,识别潜在原发灶与生存显著相关(P<0.001)。

核心结论

  • 18F-FDG PET/CT在CUP诊断流程中起补充作用,41%的病例可确定可能的原发灶。
  • 识别原发灶后总生存期改善,体现CUP患者获得诊断性18F-FDG PET/CT的价值。

研究设计与样本

  • 回顾性描述Peter MacCallum癌症中心2014至2020年诊治的颈外CUP患者,从肿瘤内科门诊和18F-FDG PET/CT记录中识别。
  • 共纳入147例患者,65%接受了分子谱分析,中位诊断年龄61岁(范围20-84岁),中位随访74个月(范围26-83个月)。
  • 由核医学专家对18F-FDG PET/CT图像进行2次独立盲法判读,与临床怀疑原发灶比较,计算灵敏度、特异度、准确率和原发灶检出率。

主要发现

  • 18F-FDG PET/CT原发灶检出率为41%,22%患者治疗方案发生改变,37%发现既往隐匿病灶。
  • 全部患者中位总生存期16.8个月;预后良好型与不良型CUP亚型分别为104.7个月和12.1个月(P<0.0001)。
  • 结合PET/CT、临床病理和基因组信息,检出与未检出原发灶者中位总生存期分别为19.8个月和8.5个月(P=0.016)。
  • 多变量分析校正年龄和性别后,识别潜在原发灶(P<0.001)、预后良好型CUP(P<0.001)和ECOG状态≤1(P<0.001)与生存显著相关。

关键数值与推荐

  • 82%患者按国际指南分类为不良型CUP亚型。
  • 18F-FDG PET/CT原发灶检出率41%,治疗改变率22%,隐匿病灶发现率37%。
  • 全部患者中位总生存期16.8个月,预后良好型104.7个月,不良型12.1个月(P<0.0001)。
  • 检出原发灶者中位总生存期19.8个月,未检出者8.5个月(P=0.016)。

临床怎么用

  • 原文结论认为18F-FDG PET/CT在CUP诊断流程中起补充作用,可确定41%病例的可能原发灶。
  • 原文结论指出识别原发灶后总生存期改善,体现CUP患者获得诊断性18F-FDG PET/CT的价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumors for which standardized diagnostic work-up fails to identify the primary site. We aimed to describe the Peter MacCallum Cancer Centre experience with 18F-FDG PET/CT in extracervical CUP with respect to detection of a primary site and its impact on management. A secondary aim was to compare overall survival (OS) in patients with and without a detected primary site. Methods: CUP patients treated between 2014 and 2020 were identified from medical oncology clinics and 18F-FDG PET/CT records. Information collated from electronic medical records included the suspected primary site and treatment details before and after 18F-FDG PET/CT. Clinicopathologic details and genomic analysis were used to determine the clinically suspected primary site and compared against 2 independent masked reads of 18F-FDG PET/CT images by nuclear medicine specialists to determine sensitivity, specificity, accuracy, and the rate of detection of the primary site. Results: We identified 147 patients, 65% of whom had undergone molecular profiling. The median age at diagnosis was 61 y (range, 20-84 y), and the median follow-up time was 74 mo (range, 26-83 mo). Eighty-two percent were classified as having an unfavorable CUP subtype as per international guidelines.18F-FDG PET/CT demonstrated a primary site detection rate of 41%, resulted in a change in management in 22%, and identified previously occult disease sites in 37%. Median OS was 16.8 mo for all patients and 104.7 and 12.1 mo for favorable and unfavorable CUP subtypes, respectively (P < 0.0001). Median OS in CUP patients when using 18F-FDG PET/CT, clinicopathologic, and genomic information was 19.8 and 8.5 mo when a primary site was detected and not detected, respectively (P = 0.016). Multivariable analysis of survival adjusted for age and sex remained significant for identification of a potential primary site (P < 0.001), a favorable CUP (P < 0.001), and an Eastern Cooperative Oncology Group status of 1 or less (P < 0.001). Conclusion: 18F-FDG PET/CT plays a complementary role in CUP diagnostic work-up and was able to determine the likely primary site in 41% of cases. OS is improved with primary site identification, demonstrating the value of access to diagnostic 18F-FDG PET/CT for CUP patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sivakumaran T, Cardin A, Callahan J, et al. Evaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary. J Nucl Med. 2024. PMID: 39237349. doi:10.2967/jnumed.123.267274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。